KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBIT: 2010-2025

Historic EBIT for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $28.4 million.

  • Rigel Pharmaceuticals' EBIT rose 102.19% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 1151.72%. This contributed to the annual value of $24.2 million for FY2024, which is 218.06% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its EBIT stood at $28.4 million for Q3 2025, which was down 53.49% from $61.1 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBIT ranged from a high of $61.1 million in Q2 2025 and a low of -$26.3 million during Q1 2022.
  • Moreover, its 3-year median value for EBIT was $2.0 million (2023), whereas its average is $9.6 million.
  • In the last 5 years, Rigel Pharmaceuticals' EBIT crashed by 162.89% in 2022 and then soared by 13,569.57% in 2025.
  • Rigel Pharmaceuticals' EBIT (Quarterly) stood at -$21.4 million in 2021, then soared by 109.71% to $2.1 million in 2022, then declined by 5.44% to $2.0 million in 2023, then skyrocketed by 747.15% to $16.7 million in 2024, then surged by 102.19% to $28.4 million in 2025.
  • Its EBIT was $28.4 million in Q3 2025, compared to $61.1 million in Q2 2025 and $12.8 million in Q1 2025.